Results 131 to 140 of about 1,124,617 (208)

Congenital Intramuscular Cavernous Hemangioma: A Rare and Underreported Entity. [PDF]

Cureus
Vignesh H, Kumar PG, Selvamuthukumaran S, B V S, K G M.   +4 more
europepmc   +1 more source

Advantages of 3D printing for soldiers’ clothing and equipment [PDF]

, 2015
Pola, Taina
core  

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. [PDF]

Clin Cancer Res
Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain DA.   +31 more
europepmc   +1 more source

Stress testing reveals selective vulnerabilities in protein homeostasis. [PDF]

Cell Rep
Aldikacti B, Putun H, Sarsani V, Zeinert R, Flaherty P, Chien P.   +5 more
europepmc   +1 more source

Ex vivo comparative study of at home bleaching products on whitening efficacy and enamel integrity. [PDF]

Sci Rep
Pasquale C, Barberis F, Lagazzo A, Ceseracciu L, Schiaffino M, Benedicenti S, Lo Bello G, Beccari C, Raiteri R, Amaroli A.   +9 more
europepmc   +1 more source

Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: a comprehensive review. [PDF]

Front Immunol
Li Y, Zhang Y, Zhu C, Han Y, Gao X, Yue J, Wang Y.   +6 more
europepmc   +1 more source

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR). [PDF]

Int J Hematol
Satake A, Nagate Y, Miyawaki K, Fujiwara Y, Ota S, Muta T, Rai S, Tsurumi H, Suzuki R, Miyake T, Goto H, Fukuhara N, Sakata-Yanagimoto M, Izutsu K, Nishikori M, Shibayama H, Kumode T, Ennishi D, Shimose T, Inubashiri N, Matsumura I, Akashi K, Kato K.   +22 more
europepmc   +1 more source

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma. [PDF]

Hematology Am Soc Hematol Educ Program
Iacoboni G, Morschhauser F.
europepmc   +1 more source

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models. [PDF]

EJHaem
Kawasaki N, Shu S, Tomita M, Liu X, Yoshiura S, Yamashita-Kashima Y.   +5 more
europepmc   +1 more source

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study. [PDF]

Ann Hematol
Yamada T, Nakamura N, Goto H, Hara T, Kasahara S, Fukuno K, Sawada M, Nakamura H, Hayase N, Goto T, Suzaki T, Fujita K, Lee S, Kanemura N, Shimizu M, Tsurumi H.   +15 more
europepmc   +1 more source